FDA Recalls Cardioplegia Solution for Lack of Sterility Assurance
The FDA has recalled Central Admixture Pharmacy Services' Cardioplegia Solution 40 mEq K due to insufficient validation data for sterilization processes. The 80-bag lot may not meet sterility standards required for cardiac use.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported hospitalizations or illnesses. The hazard is lack of sterility assurance in an injectable medication—a risk-of-harm product where injury has not yet been reported, matching the High (score 3) criterion.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling Cardioplegia Solution 40 mEq K, Warm Induction 4:1 High Potassium (500 mL IV bags). The affected lot is 36-252143 with expiration date 7/16/2023. A total of 80 bags were distributed nationwide.
The recall is due to insufficient assurance of sterility. Validation data for decontamination cycles used in manufacturing is lacking, meaning the product may not meet the sterility standards required for safe use as an injectable medication.
Healthcare providers and facilities that received this lot should stop using affected bags. For additional information about this recall, contact Central Admixture Pharmacy Services, Inc. at 2200 South 43rd Avenue, Phoenix, AZ 85043, or the FDA.
The recalled product
- Product
- CARDIOPLEGIA SOLUTION 40 mEq K, Warm Induction 4:1 High Potassium, IV Bag, total volume = 500mL, Rx only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-0002-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — IV Injectable
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 36-252143
- Exp. 7/16/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27